Shopping Cart 0
Cart Subtotal
AED 0

Swedish Orphan Biovitrum AB (SOBI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Swedish Orphan Biovitrum AB (Sobi), formerly Biovitrum AB, is an integrated biopharmaceutical company that focuses on the development of products for the treatment of rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufacturing. Its product portfolio focuses on haemophilia, inflammation and genetic and metabolic diseases. The company's products include Alprolix, Ammonaps, Elocta, Kepivance, Kineret and Orfadin. Sobi also manufactures and markets specialty and rare disease products for partner companies. It has operational presence in Europe, the Middle East and North Africa. Sobi is headquartered in Stockholm, Sweden.

Swedish Orphan Biovitrum AB (SOBI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Swedish Orphan Biovitrum AB, Medical Devices Deals, 2012 to YTD 2018 11

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deal Details 14

Private Equity 14

Swedish Orphan Biovitrum Plans to Sell Partner Products Business 14

Partnerships 15

Baylor Research Enters into Licensing Agreement with Swedish Orphan Biovitrum 15

Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ravicti 16

Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ammonaps 17

ModiQuest Research Enters into Agreement with Swedish Orphan Biovitrum 18

Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 19

Biogen's Partner Swedish Orphan Biovitrum To Exercise Its Option for Alprolix 20

Swedish Orphan Biovitrum Exercises Option Agreement with Biogen Idec for Elocta 21

Biogen Idec Expands Co-Development Agreement with Swedish Orphan Biovitrum 22

Swedish Orphan Biovitrum Enters Into Distribution Agreement With Hyperion Therapeutics 23

Auxilium Pharma Enter Into Co-Development Agreement with Swedish Orphan Biovitrum For Xiapex 24

Exelixis Amends Distribution Agreement with Swedish Orphan Biovitrum for Cometriq 25

Exelixis Enters Into Distribution Agreement With Swedish Orphan Biovitrum For Cometriq 27

Swedish Orphan Biovitrum Enters Into Distribution Agreement With Pharmaswiss 29

Swedish Orphan Biovitrum Enters Into Research Agreement With Affibody 30

Biogen Idec Amends Co-Development Agreement With Swedish Orphan Biovitrum For rFVIIIFc And rFIXFc Hemophilia Programs 31

Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 32

Licensing Agreements 33

Swedish Orphan Biovitrum Enters into Licensing Agreement with Novimmune 33

Swedish Orphan Biovitrum Enters into Licensing Agreement with Valeant Pharma 34

Swedish Orphan Biovitrum Exercises Option for Licensing Agreement with Affibody for IL-1 35

TiGenix Enters Licensing Agreement With Sobi for ChondroCelect 36

Swedish Orphan Biovitrum Enters Into Licensing Agreement With Only for Children Pharma For Neonatology Treatment 37

Swedish Orphan Biovitrum Enters Into Licensing Agreement With Amgen For Kineret And Kepivance 38

Debt Offering 40

Swedish Orphan Biovitrum Announces Private Placement Of Senior Bonds Due 2017 For USD 86 Million 40

Swedish Orphan Biovitrum AB-Key Competitors 41

Swedish Orphan Biovitrum AB-Key Employees 42

Swedish Orphan Biovitrum AB-Locations And Subsidiaries 43

Head Office 43

Other Locations & Subsidiaries 43

Recent Developments 45

Financial Announcements 45

Oct 31, 2018: Sobi publishes the report for the third quarter 2018 45

Jul 18, 2018: Sobi publishes the report for the second quarter 2018 46

Apr 26, 2018: Sobi publishes the report for the first quarter 2018 47

Feb 22, 2018: Sobi publishes its report for the fourth quarter and full-year 2017 48

Oct 25, 2017: Sobi publishes its report for the third quarter 2017 49

Jul 19, 2017: Sobi publishes its report for the second quarter 2017 50

Apr 28, 2017: Sobi publishes its report for the first quarter 2017 51

Feb 16, 2017: Sobi publishes its report for the fourth quarter and full year 2016 52

Corporate Communications 53

Aug 22, 2018: Swedish Orphan Biovitrum names Anne Marie de Jonge Schuermans as head of technical operations 53

Feb 26, 2018: Swedish Orphan Biovitrum Appoints Henrik Stenqvist As New Chief Financial Officer 54

Oct 06, 2017: Norbert Oppitz joins Sobi as new Senior Vice President, Specialty Care 55

Jun 07, 2017: Chief Operating Officer Alan Raffensperger to leave Sobi 56

May 04, 2017: Guido Oelkers Appointed President and CEO at Sobi 57

Apr 07, 2017: Theresa Heggie resigns from the Board of Directors and will not be proposed for re-election at Sobi's annual general meeting 2017 58

Jan 09, 2017: CEO Geoffrey McDonough to leave Swedish Orphan Biovitrum 59

Product News 60

12/13/2017: Sobi Launches Orfadin (nitisinone) Ambassador Program to Support Patients and Caregivers Living with Hereditary Tyrosinemia Type 1 (HT-1) 60

11/27/2017: Sobi Receives Approval From Health Canada for Orfadin (nitisinone) Oral Suspension for the Treatment of HT-1 61

09/05/2017: Sobi Receives Approval From the FDA for Once-Daily Dosing Frequency of Orfadin (nitisinone) for the Treatment of HT-1 62

05/28/2018: FDA Accepts emapalumab Biologics License Application with Priority Review 63

05/17/2017: Orfadin capsules approved in the Kingdom of Saudi Arabia for the treatment of hereditary tyrosinemia type 1 64

04/17/2018: Sobi Receives Approval from Health Canada for Once-Daily Dosing of Orfadin (nitisinone) for the Treatment of HT-1 65

03/27/2017: Novimmune opens a Branch Office in Basel 66

03/07/2017: FDA approves in-use storage at room temperature for Orfadin capsules 67

02/27/2018: Sobi's Orfadin (nitisinone) Receives Positive Reimbursement Recommendation for the Treatment of HT-1 from CADTH Canadian Drug Expert Committee 68

02/02/2017: Sobi obtains approval from the European Commission for new dosing frequency of Orfadin 69

01/04/2017: Health Canada Approves Orfadin Capsules for Treatment of Hereditary Tyrosinaemia Type-1 (HT-1) 70

Product Approvals 71

Mar 29, 2018: Novimmune submits Biologics License Application in the US for its lead drug emapalumab 71

Jan 23, 2018: FDA accepts investigational new drug application and grants Fast Track status for SOBI003 for the treatment of MPS IIIA 72

Sep 05, 2017: Novimmune Receives Rare Pediatric Disease Designation from the FDA for its Lead Drug emapalumab 73

Jul 05, 2017: FDA grants SOBI003 Orphan Drug Designation for the treatment of MPS IIIA 74

Other Significant Developments 75

May 31, 2018: Sobi discloses payments to healthcare professionals and healthcare organisations to increase transparency 75

Apr 17, 2018: Sobi publishes 2017 Annual and Sustainability Report 76

Feb 28, 2018: Sobi Launches Enhanced Corporate Sustainability Initiative 77

Jun 05, 2017: Sobi Keeps the Partner Products Business Area as an Integral Part of the Company 79

Appendix 80

Methodology 80

About GlobalData 80

Contact Us 80

Disclaimer 80


List Of Figure

List of Figures

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Swedish Orphan Biovitrum AB, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Swedish Orphan Biovitrum AB, Deals By Therapy Area, 2012 to YTD 2018 9

Swedish Orphan Biovitrum AB, Medical Devices Deals, 2012 to YTD 2018 11

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Swedish Orphan Biovitrum Plans to Sell Partner Products Business 14

Baylor Research Enters into Licensing Agreement with Swedish Orphan Biovitrum 15

Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ravicti 16

Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ammonaps 17

ModiQuest Research Enters into Agreement with Swedish Orphan Biovitrum 18

Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 19

Biogen's Partner Swedish Orphan Biovitrum To Exercise Its Option for Alprolix 20

Swedish Orphan Biovitrum Exercises Option Agreement with Biogen Idec for Elocta 21

Biogen Idec Expands Co-Development Agreement with Swedish Orphan Biovitrum 22

Swedish Orphan Biovitrum Enters Into Distribution Agreement With Hyperion Therapeutics 23

Auxilium Pharma Enter Into Co-Development Agreement with Swedish Orphan Biovitrum For Xiapex 24

Exelixis Amends Distribution Agreement with Swedish Orphan Biovitrum for Cometriq 25

Exelixis Enters Into Distribution Agreement With Swedish Orphan Biovitrum For Cometriq 27

Swedish Orphan Biovitrum Enters Into Distribution Agreement With Pharmaswiss 29

Swedish Orphan Biovitrum Enters Into Research Agreement With Affibody 30

Biogen Idec Amends Co-Development Agreement With Swedish Orphan Biovitrum For rFVIIIFc And rFIXFc Hemophilia Programs 31

Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 32

Swedish Orphan Biovitrum Enters into Licensing Agreement with Novimmune 33

Swedish Orphan Biovitrum Enters into Licensing Agreement with Valeant Pharma 34

Swedish Orphan Biovitrum Exercises Option for Licensing Agreement with Affibody for IL-1 35

TiGenix Enters Licensing Agreement With Sobi for ChondroCelect 36

Swedish Orphan Biovitrum Enters Into Licensing Agreement With Only for Children Pharma For Neonatology Treatment 37

Swedish Orphan Biovitrum Enters Into Licensing Agreement With Amgen For Kineret And Kepivance 38

Swedish Orphan Biovitrum Announces Private Placement Of Senior Bonds Due 2017 For USD 86 Million 40

Swedish Orphan Biovitrum AB, Key Competitors 41

Swedish Orphan Biovitrum AB, Key Employees 42

Swedish Orphan Biovitrum AB, Subsidiaries 43

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Swedish Orphan Biovitrum AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Swedish Orphan Biovitrum AB (Sobi), formerly Biovitrum AB, is an integrated biopharmaceutical company that focuses on the development of products for the treatment of rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufacturing. Its product portfolio focuses on haemophilia, inflammation and genetic and metabolic diseases. The company's products include Alprolix, Ammonaps, Elocta, Kepivance, Kineret and Orfadin. Sobi also manufactures and markets specialty and rare disease products for partner companies. It has operational presence in Europe, the Middle East and North Africa. Sobi is headquartered in Stockholm, Sweden.

Swedish Orphan Biovitrum AB (SOBI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Swedish Orphan Biovitrum AB, Medical Devices Deals, 2012 to YTD 2018 11

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deal Details 14

Private Equity 14

Swedish Orphan Biovitrum Plans to Sell Partner Products Business 14

Partnerships 15

Baylor Research Enters into Licensing Agreement with Swedish Orphan Biovitrum 15

Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ravicti 16

Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ammonaps 17

ModiQuest Research Enters into Agreement with Swedish Orphan Biovitrum 18

Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 19

Biogen's Partner Swedish Orphan Biovitrum To Exercise Its Option for Alprolix 20

Swedish Orphan Biovitrum Exercises Option Agreement with Biogen Idec for Elocta 21

Biogen Idec Expands Co-Development Agreement with Swedish Orphan Biovitrum 22

Swedish Orphan Biovitrum Enters Into Distribution Agreement With Hyperion Therapeutics 23

Auxilium Pharma Enter Into Co-Development Agreement with Swedish Orphan Biovitrum For Xiapex 24

Exelixis Amends Distribution Agreement with Swedish Orphan Biovitrum for Cometriq 25

Exelixis Enters Into Distribution Agreement With Swedish Orphan Biovitrum For Cometriq 27

Swedish Orphan Biovitrum Enters Into Distribution Agreement With Pharmaswiss 29

Swedish Orphan Biovitrum Enters Into Research Agreement With Affibody 30

Biogen Idec Amends Co-Development Agreement With Swedish Orphan Biovitrum For rFVIIIFc And rFIXFc Hemophilia Programs 31

Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 32

Licensing Agreements 33

Swedish Orphan Biovitrum Enters into Licensing Agreement with Novimmune 33

Swedish Orphan Biovitrum Enters into Licensing Agreement with Valeant Pharma 34

Swedish Orphan Biovitrum Exercises Option for Licensing Agreement with Affibody for IL-1 35

TiGenix Enters Licensing Agreement With Sobi for ChondroCelect 36

Swedish Orphan Biovitrum Enters Into Licensing Agreement With Only for Children Pharma For Neonatology Treatment 37

Swedish Orphan Biovitrum Enters Into Licensing Agreement With Amgen For Kineret And Kepivance 38

Debt Offering 40

Swedish Orphan Biovitrum Announces Private Placement Of Senior Bonds Due 2017 For USD 86 Million 40

Swedish Orphan Biovitrum AB-Key Competitors 41

Swedish Orphan Biovitrum AB-Key Employees 42

Swedish Orphan Biovitrum AB-Locations And Subsidiaries 43

Head Office 43

Other Locations & Subsidiaries 43

Recent Developments 45

Financial Announcements 45

Oct 31, 2018: Sobi publishes the report for the third quarter 2018 45

Jul 18, 2018: Sobi publishes the report for the second quarter 2018 46

Apr 26, 2018: Sobi publishes the report for the first quarter 2018 47

Feb 22, 2018: Sobi publishes its report for the fourth quarter and full-year 2017 48

Oct 25, 2017: Sobi publishes its report for the third quarter 2017 49

Jul 19, 2017: Sobi publishes its report for the second quarter 2017 50

Apr 28, 2017: Sobi publishes its report for the first quarter 2017 51

Feb 16, 2017: Sobi publishes its report for the fourth quarter and full year 2016 52

Corporate Communications 53

Aug 22, 2018: Swedish Orphan Biovitrum names Anne Marie de Jonge Schuermans as head of technical operations 53

Feb 26, 2018: Swedish Orphan Biovitrum Appoints Henrik Stenqvist As New Chief Financial Officer 54

Oct 06, 2017: Norbert Oppitz joins Sobi as new Senior Vice President, Specialty Care 55

Jun 07, 2017: Chief Operating Officer Alan Raffensperger to leave Sobi 56

May 04, 2017: Guido Oelkers Appointed President and CEO at Sobi 57

Apr 07, 2017: Theresa Heggie resigns from the Board of Directors and will not be proposed for re-election at Sobi's annual general meeting 2017 58

Jan 09, 2017: CEO Geoffrey McDonough to leave Swedish Orphan Biovitrum 59

Product News 60

12/13/2017: Sobi Launches Orfadin (nitisinone) Ambassador Program to Support Patients and Caregivers Living with Hereditary Tyrosinemia Type 1 (HT-1) 60

11/27/2017: Sobi Receives Approval From Health Canada for Orfadin (nitisinone) Oral Suspension for the Treatment of HT-1 61

09/05/2017: Sobi Receives Approval From the FDA for Once-Daily Dosing Frequency of Orfadin (nitisinone) for the Treatment of HT-1 62

05/28/2018: FDA Accepts emapalumab Biologics License Application with Priority Review 63

05/17/2017: Orfadin capsules approved in the Kingdom of Saudi Arabia for the treatment of hereditary tyrosinemia type 1 64

04/17/2018: Sobi Receives Approval from Health Canada for Once-Daily Dosing of Orfadin (nitisinone) for the Treatment of HT-1 65

03/27/2017: Novimmune opens a Branch Office in Basel 66

03/07/2017: FDA approves in-use storage at room temperature for Orfadin capsules 67

02/27/2018: Sobi's Orfadin (nitisinone) Receives Positive Reimbursement Recommendation for the Treatment of HT-1 from CADTH Canadian Drug Expert Committee 68

02/02/2017: Sobi obtains approval from the European Commission for new dosing frequency of Orfadin 69

01/04/2017: Health Canada Approves Orfadin Capsules for Treatment of Hereditary Tyrosinaemia Type-1 (HT-1) 70

Product Approvals 71

Mar 29, 2018: Novimmune submits Biologics License Application in the US for its lead drug emapalumab 71

Jan 23, 2018: FDA accepts investigational new drug application and grants Fast Track status for SOBI003 for the treatment of MPS IIIA 72

Sep 05, 2017: Novimmune Receives Rare Pediatric Disease Designation from the FDA for its Lead Drug emapalumab 73

Jul 05, 2017: FDA grants SOBI003 Orphan Drug Designation for the treatment of MPS IIIA 74

Other Significant Developments 75

May 31, 2018: Sobi discloses payments to healthcare professionals and healthcare organisations to increase transparency 75

Apr 17, 2018: Sobi publishes 2017 Annual and Sustainability Report 76

Feb 28, 2018: Sobi Launches Enhanced Corporate Sustainability Initiative 77

Jun 05, 2017: Sobi Keeps the Partner Products Business Area as an Integral Part of the Company 79

Appendix 80

Methodology 80

About GlobalData 80

Contact Us 80

Disclaimer 80


List Of Figure

List of Figures

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Swedish Orphan Biovitrum AB, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Swedish Orphan Biovitrum AB, Deals By Therapy Area, 2012 to YTD 2018 9

Swedish Orphan Biovitrum AB, Medical Devices Deals, 2012 to YTD 2018 11

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Swedish Orphan Biovitrum Plans to Sell Partner Products Business 14

Baylor Research Enters into Licensing Agreement with Swedish Orphan Biovitrum 15

Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ravicti 16

Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ammonaps 17

ModiQuest Research Enters into Agreement with Swedish Orphan Biovitrum 18

Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 19

Biogen's Partner Swedish Orphan Biovitrum To Exercise Its Option for Alprolix 20

Swedish Orphan Biovitrum Exercises Option Agreement with Biogen Idec for Elocta 21

Biogen Idec Expands Co-Development Agreement with Swedish Orphan Biovitrum 22

Swedish Orphan Biovitrum Enters Into Distribution Agreement With Hyperion Therapeutics 23

Auxilium Pharma Enter Into Co-Development Agreement with Swedish Orphan Biovitrum For Xiapex 24

Exelixis Amends Distribution Agreement with Swedish Orphan Biovitrum for Cometriq 25

Exelixis Enters Into Distribution Agreement With Swedish Orphan Biovitrum For Cometriq 27

Swedish Orphan Biovitrum Enters Into Distribution Agreement With Pharmaswiss 29

Swedish Orphan Biovitrum Enters Into Research Agreement With Affibody 30

Biogen Idec Amends Co-Development Agreement With Swedish Orphan Biovitrum For rFVIIIFc And rFIXFc Hemophilia Programs 31

Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 32

Swedish Orphan Biovitrum Enters into Licensing Agreement with Novimmune 33

Swedish Orphan Biovitrum Enters into Licensing Agreement with Valeant Pharma 34

Swedish Orphan Biovitrum Exercises Option for Licensing Agreement with Affibody for IL-1 35

TiGenix Enters Licensing Agreement With Sobi for ChondroCelect 36

Swedish Orphan Biovitrum Enters Into Licensing Agreement With Only for Children Pharma For Neonatology Treatment 37

Swedish Orphan Biovitrum Enters Into Licensing Agreement With Amgen For Kineret And Kepivance 38

Swedish Orphan Biovitrum Announces Private Placement Of Senior Bonds Due 2017 For USD 86 Million 40

Swedish Orphan Biovitrum AB, Key Competitors 41

Swedish Orphan Biovitrum AB, Key Employees 42

Swedish Orphan Biovitrum AB, Subsidiaries 43

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Swedish Orphan Biovitrum AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.